Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.55 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14948936 | 0.90 | GAA (0.49) | MAPTSMN1; SMN2GAAALDH3A1ALDH1A3 | |
| SCHEMBL7812585 | 0.83 | NPC1 (0.57) | SMN1; SMN2ALDH1A1MAPK1LMNANPC1 | |
| SCHEMBL11529021 | 0.83 | ALDH1A1 (0.55) | MAPTSMN1; SMN2GAAALDH1A1LMNA | |
| SCHEMBL19251504 | 0.83 | DRD2 (0.61) | MAPTSMN1; SMN2ALDH1A1CYP2D6NPC1 | |
| SCHEMBL11339430 | 0.81 | USP2 (0.45) | SMN1; SMN2GAAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL12142119 | 0.81 | DRD2 (0.62) | SIGMAR1 | |
| SCHEMBL13634469 | 0.81 | MEN1 (0.48) | MAPTSMN1; SMN2GAAALDH1A1MAPK1 | |
| SCHEMBL3850940 | 0.80 | THRB (0.47) | MAPTSMN1; SMN2ALDH1A1MAPK1CYP3A4 | |
| SCHEMBL17543217 | 0.80 | ALDH1A3 (0.42) | MAPTSMN1; SMN2GAAALDH3A1ALDH1A3 | |
| SCHEMBL12142079 | 0.80 | NOTUM (0.51) | MAPTSMN1; SMN2GAAALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | MAPT 4633/4885SMN1; SMN2 3820/4885GAA 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.